candidates for glp 1 GLP-1 medications are NOT everyone. These medications can help reduce visceral fat, improve insulin response, and support sustainable metabolic health… But they're not “quick cosmetic weight loss injections.” And In the Who is (and is Not)
Description
By contrast, Medicaid enrollment declines in 2023 saw Rxs per enrollee up from 9 prescriptions to 10 in 2023
Why this matters (and dont underestimate it): ~20% weight loss in non-diabetic obesity (REDEFINE-1) 1416% weight loss in T2D (REDEFINE-2) Dual mechanism = appetite suppression + satiety reinforcement Designed for long-term maintenance, not just short-term loss Potentially better GI tolerability with flexible titration This isnt another GLP-1. Its a clear signal that amylin is emerging as a serious second pillar in next-gen obesity care
Those with a history of severe gastrointestinal disease
On August 28, 2024, Eli Lilly and Company submitted anominationto request that its GLP-1 product, tirzepatide, be added to FDAs Demonstrable Difficulties for Compounding (DDC) lists.
Hematuria is the presence of red blood cells in the urine
Theyre typically prescribed for obesity or type 2 diabetes, with potential side effects
